About Molecular Partners
Molecular Partners is a company based in Zurich (Switzerland) founded in 2004. It operates as a HealthTech. Molecular Partners has raised $59.94 million across 3 funding rounds from investors including Index Ventures, Johnson & Johnson Innovation – JJDC and BB Biotech Ventures. The company has 174 employees as of December 31, 2024. Molecular Partners offers products and services including DARPin Therapeutics, MP0533, MP0712, and MP0317. Molecular Partners operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, Adaptive Biotechnologies, Revolution Medicines and Blueprint Medicines, among others.
- Headquarter Zurich, Switzerland
- Employees 174 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Molecular Partners Ag
-
Annual Revenue
$5.49 M (USD)-29.38as on Dec 31, 2024
-
Net Profit
$-59.65 M (USD)12.81as on Dec 31, 2024
-
EBITDA
$-64.96 M (USD)-0.27as on Dec 31, 2024
-
Total Equity Funding
$59.94 M (USD)
in 3 rounds
-
Latest Funding Round
-
Investors
Index Ventures
& 4 more
-
Employee Count
174
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Molecular Partners
Molecular Partners is a publicly listed company on the SIX with ticker symbol MOLN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Molecular Partners
Molecular Partners offers a comprehensive portfolio of products and services, including DARPin Therapeutics, MP0533, MP0712, and MP0317. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative therapies are developed using DARPin platform technology.
Tetra-specific T cell engager is designed for AML.
Radio DARPin Therapy is targeted at DLL3 protein.
Multispecific DARPin is developed for tumor-localized activation.
Unlock access to complete
Unlock access to complete
Funding Insights of Molecular Partners
Molecular Partners has successfully raised a total of $59.94M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Last Round
-
First Round
First Round
(14 Aug 2007)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2020 | Amount | Post-IPO - Molecular Partners | Valuation |
investors |
|
| Dec, 2009 | Amount | Series B - Molecular Partners | Valuation |
investors |
|
| Aug, 2007 | Amount | Series A - Molecular Partners | Valuation | Index Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Molecular Partners
Molecular Partners has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Index Ventures, Johnson & Johnson Innovation – JJDC and BB Biotech Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology startups and entrepreneurs.
|
Founded Year | Domain | Location | |
|
Venture capital firm backed by Johnson & Johnson
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Molecular Partners
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Molecular Partners
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Molecular Partners Comparisons
Competitors of Molecular Partners
Molecular Partners operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, Adaptive Biotechnologies, Revolution Medicines and Blueprint Medicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Molecular Partners
Frequently Asked Questions about Molecular Partners
When was Molecular Partners founded?
Molecular Partners was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Where is Molecular Partners located?
Molecular Partners is headquartered in Zurich, Switzerland.
Is Molecular Partners a funded company?
Molecular Partners is a funded company, having raised a total of $59.94M across 3 funding rounds to date. The company's 1st funding round was a Series A of $15.4M, raised on Aug 14, 2007.
How many employees does Molecular Partners have?
As of Dec 31, 2024, the latest employee count at Molecular Partners is 174.
What is the annual revenue of Molecular Partners?
Annual revenue of Molecular Partners is $5.49M as on Dec 31, 2024.
What does Molecular Partners do?
Molecular Partners is engaged in the development of innovative DARPin therapeutics targeting cancer and other serious diseases. The company operates within the biotechnology sector, focusing on solutions like radiopharmaceuticals, immune cell engagers, and multispecific therapies. Programs such as MP0533 for AML, MP0712 for Radio DARPin Therapy, and MP0317 for solid tumors are being advanced. Platforms like Switch-DARPin for conditional immune activation are also utilized to address unmet medical needs in oncology.
Who are the top competitors of Molecular Partners?
Molecular Partners's top competitors include Moderna, Jazz Pharmaceuticals and C4 Therapeutics.
What products or services does Molecular Partners offer?
Molecular Partners offers DARPin Therapeutics, MP0533, MP0712, and MP0317.
Is Molecular Partners publicly traded?
Yes, Molecular Partners is publicly traded on SIX under the ticker symbol MOLN.
Who are Molecular Partners's investors?
Molecular Partners has 5 investors. Key investors include Index Ventures, Johnson & Johnson Innovation – JJDC, BB Biotech Ventures, Endeavour Vision, and EW Healthcare Partners.
What is Molecular Partners's ticker symbol?
The ticker symbol of Molecular Partners is MOLN on SIX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.